secwatch / observer
8-K filed June 16, 2023, 7:59 PM ET ticker ARCT CIK 0001768224
other material confidence high sentiment neutral materiality 0.15

Arcturus Therapeutics stockholders elect eight directors, approve say-on-pay and auditor ratification at annual meeting

Arcturus Therapeutics Holdings Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcturus Therapeutics Holdings Inc. shareholders approved To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz and Dr. John H. Markels to the Board of Directors at the 2023-06-14 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-14
Exact text from the filing
(1) To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz and Dr. John H. Markels to the Board of Directors
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcturus Therapeutics Holdings Inc. shareholders approved To approve, on a non-binding advisory basis, the resolution approving named executive officer compensation (say-on-pay) at the 2023-06-14 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-06-14
Exact text from the filing
Approval, on a non-binding advisory basis, the resolution approving named executive officer compensation , referred to as "say-on-pay," as provided in Proposal Number 2 of the Proxy Statement: 11,959,501 4,562,055 15,403 2,450,043
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Arcturus Therapeutics Holdings Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-14 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-14
Exact text from the filing
Approval of the ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023, as provided in Proposal Number 3 of the Proxy Statement: 18,955,484 22,224 9,294 N/A
View on SEC.gov

Browse all shareholder votes →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR
accession 0001193805-23-000861
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.